-

02:08:46 PM

FEMY Stock News

FEMY - Femasys Inc

09/27/23 8:00 AM

Nasdaq : FEMY

conferenceslow float

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies - FemBloc is being developed as a first-of-its-kind, non-surgical permanent birth control with a clear U.S. regulatory pathway - ATLANTA, Sept. 27, 2023 (GLOBE

RHEA-AI

neutral

09/25/23 5:25 PM

Nasdaq : FEMY

clinical triallow float

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ® , an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to

RHEA-AI

positive

09/20/23 8:30 AM

Nasdaq : FEMY

clinical triallow float

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including two lead revolutionary late-clinical stage product candidates and

RHEA-AI

neutral

09/06/23 8:30 AM

Nasdaq : FEMY

conferenceslow float

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative

RHEA-AI

neutral

08/31/23 8:30 AM

Nasdaq : FEMY

low float

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative

RHEA-AI

neutral

08/10/23 8:00 AM

Nasdaq : FEMY

earningslow float

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc ® - Three product approvals achieved in Canada for FemaSeed ® , FemCerv ® and FemCath ® products during the second quarter - Raised $3.9 million in a registered direct offering ATLANTA, Aug. 10, 2023

RHEA-AI

neutral

08/03/23 8:45 AM

Nasdaq : FEMY

low float

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative

RHEA-AI

neutral

07/27/23 8:45 AM

Nasdaq : FEMY

low float

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of

RHEA-AI

neutral

06/26/23 8:00 AM

Nasdaq : FEMY

clinical trialfda approvallow float

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies

RHEA-AI

neutral

06/15/23 8:00 AM

Nasdaq : FEMY

managementlow float

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

Femasys Inc. (NASDAQ: FEMY), a biomedical

RHEA-AI

neutral

FEMY Data

IndustrySurgical and Medical Instrument Manufacturing
Security nameFemasys Inc
SectorManufacturing

About Femasys Inc

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t